These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26448366)

  • 1. Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients.
    Almroth G; Lönn J; Uhlin F; Brudin L; Andersson B; Hahn-Zoric M
    Scand J Immunol; 2016 Jan; 83(1):58-63. PubMed ID: 26448366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
    Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
    Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
    Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
    Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
    Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
    Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management?
    Tan SJ; Cai MM
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():14-18. PubMed ID: 28429560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.
    Park MY; Herrmann SM; Saad A; Eirin A; Tang H; Lerman A; Textor SC; Lerman LO
    Clin J Am Soc Nephrol; 2015 Mar; 10(3):443-51. PubMed ID: 25542906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.
    Desbiens LC; Sidibé A; Ung RV; Fortier C; Munger M; Wang YP; Bisson SK; Marquis K; Agharazii M; Mac-Way F
    Osteoporos Int; 2018 Oct; 29(10):2345-2353. PubMed ID: 29959497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients.
    Lee YT; Ng HY; Chiu TT; Li LC; Pei SN; Kuo WH; Lee CT
    Clin Chim Acta; 2016 Jan; 452():38-43. PubMed ID: 26522655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study.
    Brandenburg VM; Kramann R; Koos R; Krüger T; Schurgers L; Mühlenbruch G; Hübner S; Gladziwa U; Drechsler C; Ketteler M
    BMC Nephrol; 2013 Oct; 14():219. PubMed ID: 24112318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis.
    Filiopoulos V; Hadjiyannakos D; Takouli L; Metaxaki P; Sideris V; Vlassopoulos D
    Int J Artif Organs; 2009 Dec; 32(12):872-82. PubMed ID: 20037892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease.
    de Oliveira RA; Barreto FC; Mendes M; dos Reis LM; Castro JH; Britto ZM; Marques ID; Carvalho AB; Moysés RM; Jorgetti V
    Kidney Int; 2015 May; 87(5):1039-45. PubMed ID: 25493951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients.
    Fukasawa H; Ishigaki S; Kinoshita-Katahashi N; Niwa H; Yasuda H; Kumagai H; Furuya R
    Nephrology (Carlton); 2014 Dec; 19(12):784-90. PubMed ID: 25185859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.
    Perna AF; Pizza A; Di Nunzio A; Bellantone R; Raffaelli M; Cicchella T; Conzo G; Santini L; Zacchia M; Trepiccione F; Ingrosso D
    J Ren Nutr; 2017 Nov; 27(6):453-457. PubMed ID: 29056164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines, adipocytokines and inflammatory markers in patients on continuous ambulatory peritoneal dialysis and hemodialysis.
    Oncel M; Akbulut S; Toka Ozer T; Kiyici A; Keles M; Baltaci B; Turk S
    Ren Fail; 2016 Aug; 38(7):1071-5. PubMed ID: 27267129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
    Asamiya Y; Yajima A; Shimizu S; Otsubo S; Tsuchiya K; Nitta K
    Osteoporos Int; 2015 Mar; 26(3):1017-28. PubMed ID: 25366373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.